BCT.TO BriaCell Therapeutics Corp.
TSXHealthcareAs of 2026-05-29 15:59
Valuation
View DetailsP/E (TTM)
-0.34
PEG
—
P/B
0.33
P/S
0.00
EV/EBITDA
0.75
DCF Value
—
FCF Yield
-451.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-166.3%
ROA
-88.2%
ROIC
-100.9%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $0.00 | $-7.2M | $-2.58 |
| Q1 2026 | $0.00 | $-8.2M | $-4.35 |
| Q4 2025 | $0.00 | $-8.1M | $-4.28 |
| Q3 2025 | $0.00 | $-6.1M | $-16.40 |
Latest News
Listing Info
Market
US
Exchange
TSX
Currency
USD
Sector
Healthcare
Industry
Biotechnology
Country
CA
BriaCell Therapeutics Corp., an immuno-oncology-focused biotechnology company, engages in developing immunotherapies for the management of cancer. Its lead drug candidate is Bria-IMT, a whole-cell cancer vaccine that is in Phase I/IIa clinical trials in combination with the immunotherapy development candidates retifanlimab. The company is also developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test that determines the patients' HLA types. It has a non-exclusive clinical trial collaboration with Incyte Corporation to evaluate the effects of combinations of novel clinical candidates; and a cooperative research and development agreement with the National Cancer Institute to conduct preclinical studies to develop and test Bria-OTS cellular immunotherapy as a treatment for cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.